MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 540084 | Name: Clopidogrel Sulfate (racemic)
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Clopidogrel Sulfate is a P2Y12 receptor antagonist used to treat coronary artery disease and peripheral vascular disease and to prevent myocardial infarction and stroke.

Chemical Structure

Clopidogrel Sulfate (racemic)
Clopidogrel Sulfate (racemic)
CAS#90055-48-4 (racemic)

Theoretical Analysis

MedKoo Cat#: 540084

Name: Clopidogrel Sulfate (racemic)

CAS#: 90055-48-4 (racemic)

Chemical Formula: C16H18ClNO6S2

Exact Mass: 419.0264

Molecular Weight: 419.89

Elemental Analysis: C, 45.77; H, 4.32; Cl, 8.44; N, 3.34; O, 22.86; S, 15.27

Price and Availability

Size Price Availability Quantity
5mg USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
120202-66-6 (sulfate) 120202-65-5 (HCl) 90055-48-4 (racemic) 744256-69-7 (besylate) 120202-67-7 (HBr)
Synonym
Clopidogrel hydrogen sulfate; Myogrel; SR 25990C; SR-25990C; SR-25990C;
IUPAC/Chemical Name
methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate sulfate
InChi Key
FDEODCTUSIWGLK-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H16ClNO2S.H2O4S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;1-5(2,3)4/h2-5,7,9,15H,6,8,10H2,1H3;(H2,1,2,3,4)
SMILES Code
O=C(OC)C(C1=CC=CC=C1Cl)N2CCC3=C(C=CS3)C2.O=S(O)(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Clopidogrel hydrogen sulfate is an antiplatelet agent which works by blocking platelets from sticking together and prevents them from forming harmful clots.
In vitro activity:
DNA fragmentation was found to be increased as a response to 7.5 µM, 40 µM and 75 µM clopidogrel treatment compared to non-treated control groups in AML-12 hepatocytes (p<0.01, p<0.001, p<0.01 respectively) and 3T3-L1 adipocytes (p<0.001, p<0.001 and p<0.001 respectively). DNA damage levels as a response to clopidogrel treatment was found to be higher in 3T3-L1 adipocytes than AML-12 hepatocytes. Reference: Curr Drug Saf. 2021 Jan 6. https://pubmed.ncbi.nlm.nih.gov/33413066/
In vivo activity:
The effects of intravenous ADP infusions of 2-8mg/kg/hour were examined in anesthetized Wistar rats that were untreated or chronically pretreated with clopidogrel, 20mg/kg/24hours, a selective P2Y12-R antagonist. ADP induced a gradual, dose-dependent 15% decrease of mean arterial pressure, a sustained increase of renal blood flow and a 25% decrease in renal vascular resistance. Clopidogrel pretreatment attenuated the mean arterial pressure decrease, and did not significantly alter renal blood flow or renal vascular resistance. Reference: Am J Med Sci. 2018 Sep;356(3):287-295. https://pubmed.ncbi.nlm.nih.gov/30293555/

Preparing Stock Solutions

The following data is based on the product molecular weight 419.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Bayar E, Cevik M, Caker S, Cagatay P, Susleyici B. DNA Damage in AML-12 Hepatocytes and 3T3-L1 Adipocytes Treated with Clopidogrel. Curr Drug Saf. 2021 Jan 6. doi: 10.2174/1574886315666210106141936. Epub ahead of print. PMID: 33413066. 2. Roszkowska-Chojecka MM, Walkowska A, Sadowski J, Dobrowolski L. Clopidogrel Partially Counteracts Adenosine-5'-Diphosphate Effects on Blood Pressure and Renal Hemodynamics and Excretion in Rats. Am J Med Sci. 2018 Sep;356(3):287-295. doi: 10.1016/j.amjms.2018.04.013. Epub 2018 Apr 27. PMID: 30293555.
In vitro protocol:
1. Bayar E, Cevik M, Caker S, Cagatay P, Susleyici B. DNA Damage in AML-12 Hepatocytes and 3T3-L1 Adipocytes Treated with Clopidogrel. Curr Drug Saf. 2021 Jan 6. doi: 10.2174/1574886315666210106141936. Epub ahead of print. PMID: 33413066.
In vivo protocol:
1. Roszkowska-Chojecka MM, Walkowska A, Sadowski J, Dobrowolski L. Clopidogrel Partially Counteracts Adenosine-5'-Diphosphate Effects on Blood Pressure and Renal Hemodynamics and Excretion in Rats. Am J Med Sci. 2018 Sep;356(3):287-295. doi: 10.1016/j.amjms.2018.04.013. Epub 2018 Apr 27. PMID: 30293555.
1: Lian WQ, Gong AQ, Wang L, Zhu XS. [Determination of clopidogrel sulfate in pharmaceutical formulation and biological fluids by extraction spectrofluorimetric method]. Guang Pu Xue Yu Guang Pu Fen Xi. 2014 Nov;34(11):3030-3. Chinese. PubMed PMID: 25752052. 2: Yang YG, Zhang M, Jiang N, Song LX, Xu XT, Di XH, Xu L, Xu J, Zhao GT. Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. Genet Mol Res. 2015 Dec 14;14(4):16736-43. doi: 10.4238/2015.December14.1. PubMed PMID: 26681020. 3: Tsoumani ME, Kalantzi KI, Goudevenos IA, Tselepis AD. Clopidogrel generic formulations in the era of new antiplatelets: a systematic review. Curr Vasc Pharmacol. 2014;12(5):766-77. Review. PubMed PMID: 23885646. 4: Tsoumani ME, Kalantzi KI, Dimitriou AA, Ntalas IV, Goudevenos IA, Tselepis AD. Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate. Expert Opin Pharmacother. 2012 Feb;13(2):149-58. doi: 10.1517/14656566.2012.644536. Epub 2011 Dec 21. PubMed PMID: 22188544. 5: Ryu JH, Kim SJ. Clopidogrel effectively suppresses endothelial microparticle generation induced by indoxyl sulfate via inhibition of the p38 mitogen-activated protein kinase pathway. Blood Purif. 2011;32(3):186-94. doi: 10.1159/000326297. Epub 2011 Jul 29. PubMed PMID: 21811066. 6: Tsoumani ME, Kalantzi KI, Dimitriou AA, Ntalas IV, Goudevenos IA, Tselepis AD. Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate. Angiology. 2012 Oct;63(7):547-51. doi: 10.1177/0003319711427697. Epub 2011 Dec 5. PubMed PMID: 22144668. 7: Bali DE, Osman MA, El Maghraby GM. Enhancement of Dissolution Rate and Intestinal Stability of Clopidogrel Hydrogen Sulfate. Eur J Drug Metab Pharmacokinet. 2016 Dec;41(6):807-818. PubMed PMID: 26620370. 8: Srivastava A, Mishra R, Tandon P, Bansal AK. FT-Raman, FT-IR, UV spectroscopic, NBO and DFT quantum chemical study on the molecular structure, vibrational and electronic transitions of clopidogrel hydrogen sulfate form 1: a comparison to form 2. Spectrochim Acta A Mol Biomol Spectrosc. 2013 Mar;104:409-18. doi: 10.1016/j.saa.2012.11.093. Epub 2012 Dec 5. PubMed PMID: 23277180. 9: Wang SH, Li X, Hou FL, Tian YJ, Liu YH, Zheng SL. Comparison of the antiplatelet effect of clopidogrel benzene sulfonate and clopidogrel hydrogen sulfate in stable coronary heart disease. Genet Mol Res. 2016 Apr 25;15(2). doi: 10.4238/gmr.15027136. PubMed PMID: 27173230. 10: Ntalas IV, Kalantzi KI, Tsoumani ME, Vakalis JN, Vasilakopoulos V, Vardakis K, Vemmos KN, Voukelatou M, Giannakoulas G, Giatrakos I, Giogiakas V, Goumas G, Dimoulis N, Draganigos A, Efthimiadis I, Thoma M, Kazakos E, Kipouridis N, Konstantinou S, Bourdakis A, Nikolopoulos D, Peltekis L, Prokopakis N, Sinteles I, Stroumbis CS, Terzoudi K, Tsilias K, Xaraktsis I, Charmpas C, Hatziathanasiou G, Christogiannis Z, Panagiotakos DB, Goudevenos JA, Tselepis AD. Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial. Curr Vasc Pharmacol. 2015;13(6):809-18. PubMed PMID: 25782408. 11: Hagiwara S, Iwasaka H, Hasegawa A, Oyama M, Imatomi R, Uchida T, Noguchi T. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock. 2011 Mar;35(3):289-92. doi: 10.1097/SHK.0b013e3181f48987. PubMed PMID: 20720514. 12: Meves SH, Overbeck U, Kaiser A, Krogias C, Neubauer H. [Switching from clopidogrel hydrogen sulfate to clopidogrel besylate. Impaired antiplatelet effect in patients with ischemic stroke]. Nervenarzt. 2010 Aug;81(8):992-7. doi: 10.1007/s00115-010-3028-2. German. PubMed PMID: 20517690. 13: Garg N, Rajpurohit N, Flaker G. Clopidogrel hydrogen sulphate for atrial fibrillation. Expert Opin Pharmacother. 2011 Aug;12(11):1781-7. doi: 10.1517/14656566.2011.587118. Epub 2011 Jun 11. Review. PubMed PMID: 21663525. 14: Pindelska E, Szeleszczuk L, Pisklak DM, Mazurek A, Kolodziejski W. Solid-state NMR as an effective method of polymorphic analysis: solid dosage forms of clopidogrel hydrogensulfate. J Pharm Sci. 2015 Jan;104(1):106-13. doi: 10.1002/jps.24249. Epub 2014 Nov 12. PubMed PMID: 25393324. 15: Winning J, Claus RA, Pletz MW, Bauer M, Lösche W. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock. 2011 Sep;36(3):317; author reply 317-8. doi: 10.1097/SHK.0b013e318224f66a. PubMed PMID: 21844789. 16: Oberhänsli M, Lehner C, Puricel S, Lehmann S, Togni M, Stauffer JC, Baeriswyl G, Goy JJ, Cook S. A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial. Arch Cardiovasc Dis. 2012 Nov;105(11):587-92. doi: 10.1016/j.acvd.2012.06.001. Epub 2012 Oct 4. PubMed PMID: 23177487. 17: Lassoued MA, Sfar S, Bouraoui A, Khemiss F. Absorption enhancement studies of clopidogrel hydrogen sulphate in rat everted gut sacs. J Pharm Pharmacol. 2012 Apr;64(4):541-52. doi: 10.1111/j.2042-7158.2011.01434.x. Epub 2011 Dec 29. PubMed PMID: 22420660. 18: Miranda MC. [Reversible ageusia associated with clopidogrel use]. Rev Med Chil. 2012 Sep;140(9):1230-1. doi: 10.4067/S0034-98872012000900020. Spanish. PubMed PMID: 23354649. 19: Sadeghi-Ghahrody M, Yousefi-Malekshah SH, Karimi-Sari H, Yazdanpanah H, Rezaee-Zavareh MS, Yavarahmadi M. Bleeding after tooth extraction in patients taking aspirin and clopidogrel (Plavix®) compared with healthy controls. Br J Oral Maxillofac Surg. 2016 Jun;54(5):568-72. doi: 10.1016/j.bjoms.2016.02.036. Epub 2016 Mar 11. PubMed PMID: 26975576. 20: Rao KR, Lakshmi KR. Design, development and evaluation of clopidogrel bisulfate floating tablets. Int J Pharm Investig. 2014 Jan;4(1):19-26. doi: 10.4103/2230-973X.127736. PubMed PMID: 24678458; PubMed Central PMCID: PMC3944613.

View History

Diphemanil

Diphemanil